GlassScriptPhysician profile
Barry E Newton
NPI 1396883989
$2,687.41
in general payments reported to CMS, 2019-2025
18 companies · $931 in 2025
The $931 reported for 2025 was more than what 79% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $835 · 2022: $505 · 2023: $71.87 · 2024: $345 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,253 · Education: $94.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,253.34 |
| Education | $94.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $486.17 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $346.67 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $253.35 | 2021-2025 | |
| Lilly USA, LLC | $229.63 | 2021-2025 | Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $217.79 | 2021-2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $190.06 | 2021-2025 | Cabtreo, Jublia |
| Organogenesis INC. | $180.49 | 2021-2025 | Apligraf |
| Janssen Biotech, INC. | $171.22 | 2021-2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $163.03 | 2021-2025 | |
| Ucb, INC. | $100.83 | 2021-2025 | Bimzelx |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.48 | 2024-2025 | Spevigo |
| Leo Pharma INC. | $51.95 | 2024-2025 | Adbry |
| Almirall LLC | $42.64 | 2024-2025 | Klisyri |
| E.R. Squibb & Sons, L.L.C. | $39.26 | 2025 | Sotyktu |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $32.76 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Pfizer INC. | $21.71 | 2025 | |
| Amgen INC. | $18.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Newton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.